F. Orlanducci

发表

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML

D. Olive, D. Blaise, A. Toubert, 2017, Oncoimmunology.

Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia

S. Granjeaud, D. Olive, D. Blaise, 2015, Front. Immunol..

Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy.

D. Olive, C. Richon, B. Janji, 2022, Cancer research.

Persistence of natural killer cells with expansion of a hypofunctional CD56-CD16+KIR+NKG2C+ subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency.

A. Fischer, D. Olive, C. Picard, 2013, The Journal of allergy and clinical immunology.

The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.

R. Bouabdallah, L. Xerri, D. Olive, 2013, Blood.

T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions.

F. Orlanducci, P. Dietrich, M. Courtier, 1994, Journal of immunology.

Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy

R. Bouabdallah, D. Olive, D. Coso, 2012, Journal of Clinical Immunology.

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

D. Olive, F. Orlanducci, J. Rey, 2009 .

ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy.

D. Olive, C. Richon, B. Janji, 2014, Cancer research.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

S. Granjeaud, D. Olive, A. Toubert, 2017, Front. Immunol..

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia

D. Olive, F. Orlanducci, A. Le Roy, 2016, Oncoimmunology.

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

S. Granjeaud, D. Olive, D. Blaise, 2021, Proceedings of the National Academy of Sciences.

High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome

S. Granjeaud, D. Olive, D. Blaise, 2020, medRxiv.

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells

D. Olive, C. Fauriat, F. Orlanducci, 2017, Front. Immunol..

ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.

P. Gaulard, R. Bouabdallah, D. Olive, 2020, Blood advances.

CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.

K. Tarte, R. Bouabdallah, S. Granjeaud, 2018, Blood advances.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

S. Granjeaud, D. Olive, A. Cerwenka, 2017, Oncotarget.

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities

S. Granjeaud, D. Olive, J. Mege, 2018, Front. Immunol..

Targeting BTN2A1 enhances Vγ9Vδ2 T cell effector functions and triggers tumor cells pyroptosis

D. Olive, C. Cano, F. Orlanducci, 2023, bioRxiv.

Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells

D. Olive, F. Orlanducci, N. Vey, 2023, Cells.